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Abstract 
Shortly after intermittent haemodialysis became established treatment of chronic renal failure, the first wearable 
artificial kidney (WAK) device projected or even constructed to solve the problem of intermittent treatment 
unphysiology. Successful development of hollow fibres enabled construction of a sufficiently small dialyzer to be worn 
and recirculation of dialysate through a sorbent cartridge lead to tremendous drop in dialysate volumes needed. Tested 
were WAK devices based both on haemodialysis (HD) or on haemofiltration (HF) (after highly permeable membranes 
became available) as well as on peritoneal dialysis (PD). Later, some other techniques and processes appeared in 
armamentarium of WAK designers, such as charged membranes, electrodialysis, nanotechnological processes enabling 
to create membranes with solute-specific pores. Also a few hybride constructions appeared during the last decade using 
membranes coated with tubular epithelial cells to mimic tubular resorption of biological kidney. With current trends 
towards more frequent HD with higher material costs, WAK effort got another impetus, this time purely economical. 
The first commercially available WAK (although still waiting for a CE mark in Europe and FDA clearing in USA) was 
developed by a Singaporean company AWAK Technologies in 2011. A European WAK is being developed as a joint 
project in frame of FP7 and is expected to be ready by 2014. However, acceptance of WAK instead of conventional 
intermittent therapy both by physicians and by the patients themselves still remains unresolved. 
 
Keywords 
Wearable artificial kidney, haemodialysis, peritoneal dialysis, sorption, bioartificial device 
 
Introduction 
 
 
 
 
The kidney was the first organ function of which 
was successfully replaced by an artificial technical 
device on long term. Haemodialysis (HD)-based 
artificial kidney was however by no means perfect. 
Nephron, the principal functional unit of biological 
kidney, is a two-stage system. The first one – 
glomerulus – produces so called primary urine (in 
fact plasma filtrate) by filtration. The second one – 
tubulus – ensures resorption of all solutes needed in 
the organism and only true waste leaves kidney in 
final urine. HD has replaced this two-stage system 
by just single-stage process – diffusion and 
filtration across the dialyzer membrane. However, 
diffusion efficiency quickly decreases with 
increasing molecular weight of the diffusing solute 
while filtration in glomeruli excretes all solutes in 
the same rate irrespective of their molecular weight. 
Although with the introduction of convective 
techniques such as haemodiafiltration (HDF) or 
haemofiltration (HF) solute removal has got much 
closer to biological kidney function, the second 
principal difference of artificial kidney from its 
biological counterpart – intermittent character of its 
application – remained preserved. Most patients 
dialyse thrice weekly for 3 to 5 hours while 
biological kidney works 24 hours a day, 7 days a 
week. Direct consequence of that imperfect 
substitute is an unphysiologically high cyclic 
variation in many biochemical parameters as well 
as in hydration. Carl Kjellstrand even considered 
this unphysiology the main cause of dialysis side 
effects already in mid-seventies (1). Inspired by the 
Kjellstrand´s work, a mathematical theory was 
developed at Prague-Strahov dialysis department 
(2). It was based on a plot with blood urea time-
averaged concentration (TAC) on X-axis and its 
time-averaged deviation (TAD) on Y-axis and 
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clearly showed how far the different then existing 
dialysis techniques were from “normal” healthy 
situation with continuous kidney function (see 
Fig. 1). Yet continuous application of then 
stationary artificial kidney would mean to 
immobilize the patient. To solve this problem, 
wearable (WAK) or even implantable artificial 
kidney appeared to be the right concept. 
 
 
Key pre-requisites of WAK and 
evolution of its concepts 
 
There were two main obstacles to converting an 
HD device of the sixties or seventies into a WAK – 
too big dialyzer to be worn and the large amount of 
 
Fig. 1: The TAC/TAD concept to assess dialysis 
adequacy: TAC (plasma urea time-average 
concentration) shows the weekly mean around 
which the actual concentration fluctuates, TAD 
(plasma urea time-averaged deviation) shows mean 
fluctuation around the TAC value and serves as a 
marker of physiology of a certain treatment method 
or schedule; dashed line on small plots at the axes 
with weekly plasma urea (CP) profile define the 
TAC and TAD; (CAPD stands for continuous 
ambulatory peritoneal dialysis, APD for automated 
peritoneal dialysis, and NPD for night peritoneal 
dialysis) 
 
 
 
dialysate needed for an efficient HD. However, pre-
requisites to solve both problems appeared 
relatively early in HD history: Capillary dialyzer 
developed in the sixties had low blood volume and 
possessed apparently sufficient potential for further 
miniaturisation and the works of Yatzidis (3) on 
adsorption of uraemic toxins on charcoal suggested 
that sorption could do away with the large amounts 
of dialysis fluid. It did not go unnoticed. Already 
two years later Blaney suggested use of adsorption 
on charcoal in WAK (4). However, a serious 
problem was detected – insufficient affinity of 
charcoal to urea, the most abundant waste 
metabolite. It was first shown by Dharnidharka (5) 
from Kolff´s group – while concentration of urea 
and creatinine was brought close to zero by 
circulation of blood via charcoal, drop in urea 
concentration was much less pronounced. The 
patented idea of Blackshear to cool the charcoal 
cartridge down close to 0°C where its affinity to 
urea sharply increases (6) has proved rather 
impractical. The idea of Gordon to convert 
electroneutral molecules of urea in ammonium ions 
by means of the enzyme urease (7) and remove 
those ions by a suitable ion-exchanger appeared 
much more viable. Based on this idea, the first truly 
portable HD system REDY was then built by a 
Dutch company Organon Teknika – Fig. 2. It 
worked with only five litres of dialysate which 
recirculated via a sorption cartridge containing 
charcoal, urease layer and zirconium phosphate. 
The issue of calcium and magnesium ions removal 
together with ammonium was solved by slow 
continuous infusion of calcium and magnesium 
chloride into dialysate during HD. The REDY 
cartridge subsequently became a favourite 
component of many WAK constructions throughout 
the seventies and eighties. 
 
 
 
 
 
Fig. 2: Haemodialysis system REDY manufactured 
in the seventies and eighties by Organon Teknika, 
NL; dialysate volume needed per dialysis: 5 litres; 
composition of the disposable sorbent cartridge: 
charcoal (to remove waste metabolites except 
urea), urease layer (to convert urea into ammonium 
ions), ion exchanger (to remove the ammonium 
ions), 
(http://www.advancedrenaleducation.com/sorbentte
chnology/ ) 
 
 
The seventies were a very fruitful era in WAK 
construction efforts. Probably the most active was 
REVIEW 
 
7 
 
the team of dr. Kolff in Salt Lake City, Utah. They 
developed both peritoneal dialysis (PD) and HD-
based WAK using a capillary dialyzer and charcoal 
or later the REDY cartridge – Fig. 3 a, b (8).  
 
Fig. 3: different WAK constructions from the 
Kolff´s group in the seventies: 
Upper picture – PD-based WAK with a secondary 
dialyzer circuit to clean peritoneal dialysate partly 
by diffusion against dialysate in the tank and partly 
by sorption on charcoal 
Bottom picture – HD-based WAK with the REDY 
sorbent cartridge in dialysate circuit. 
 
But different WAK projects were running in a 
few other countries, too. Henne in Wuppertal, 
Germany, used a dialyzer with surface area of 
0,1 m2 and just one litre of dialysate which was 
changed every two hours. However, he did not use 
any sorption cartridge but added sorbent powder 
directly into dialysate (9). In the end of the 
seventies, theory of middle molecules uraemic 
toxins emerged and use of more porous membrane 
started to be endorsed. It affected also the WAK 
field. Otuba constructed his WAK in Tokyo as a 
double stage device, combining a plasmafilter and 
sorption cartridge in the first stage followed by a 
high-flux ultrafilter (10) and tested it with dogs. An 
entirely novel approach was tested by Neff – a 
haemofilter connected to a Scribner shunt (i.e. 
without a blood pump) generated about 0,5 litre of 
filtrate per hour, but instead of regenerating it with 
a usual sorption cartridge he discarded all the 
filtrate and provided the patients with orally 
administered substitution fluid (11). Four-days of 
reported in vivo use did not result in any diarhea or 
any other gastrointestinal problems. 
     With establishment of sufficient dialysis 
infrastructure able to cover dialysis needs in 
developed countries in the eighties, work on WAK 
lost a lot of its momentum. Yet one achievement 
must be mentioned from that period: Using 
conventional continuous arterio-venous 
haemofiltration with filtrate processed via a 
sorption cartridge, A. Murisasco treated one patient 
for 1 month and another one even for three month 
(12) – a record not outdone since then! In the early 
nineties, an idea of using charged membrane to 
separate removal of urea from removal of other 
waste metabolites came from Japan. Tada´s 
haemofiltration (HF)-based device (13) is depicted 
on Fig. 4: Filtrate obtained in the first haemofilter  
 
Fig. 4: Haemofiltration-based WAK of Tada and 
co-workers (Tokyo, 1990): Primary circuit – 
generation of filtrate in a conventional haemofilter; 
Secondary circuit – recirculation of filtrate via 
charcoal and a special dialyzer with highly 
positively charged membrane allowing diffusional 
passage of only electroneutral solutes (urea) to the 
Tertiary circuit – low volume dialysate 
recirculation via urease (conversion of urea into 
ammonium aions) and an ion-exchanger (removal 
of ammonium ions). 
 
recirculated via secondary circuit with a pure 
charcoal where most waste metabolites except for 
urea were removed. In series with the charcoal 
cartridge was a special dialyzer with highly 
positively charged membrane. That charge 
effectively blocked diffusion of any cations (Ca2+, 
Mg2+ etc.) but allowed unrestricted diffusion of urea 
into a tertiary circuit with urease and ion-exchanger 
for ammonium ions removal. It is interesting to 
note, that according to the 2010 annual report also 
Fresenius company, currently number one among 
dialysis manufacturers, did some WAK-related 
experiments using charged membranes. 
 
Research and development in WAK 
field after 2000 
 
With the introduction of highly porous 
membranes and convective techniques, the 
conventional thrice weekly treatment has reached a 
sort of its limit and further improvement is likely to 
result from introduction of more physiological 
regimens. In 2004, the International Quotidian 
Dialysis Registry was started to prove that more 
frequent and thus more physiological schedules are 
the right way ahead in renal replacement therapy 
(RRT). It currently registers some 5000 patients 
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worldwide and reported treatment outcomes are 
impressive (14). However, as the material costs for 
quotidian HD are apparently higher than for 
conventional 3x weekly HD (5-7 dialyzers and 
blood lines are needed instead of 3), WAK with its 
expected device exchanges and/or checks once 
weekly or even bi-weekly gained a new impetus, 
this time purely economical. It is the “belt” WAK 
of V. Gura from United States which has gained the 
widest publicity during the last decade - Fig. 5,  
 
Fig. 5: “Belt” WAK of V. Gura: continuous 
haemodialysis combined with already “classical” 
sorption in the dialysate circuit (charcoal, urease, 
ion-exchanger), novel is the double pulsing pump 
driving both blood and dialysate and alkalisation of 
dialysate after passage through the urease to 
increase efficacy of ammonium ions removal on the 
ion-exchanger  
(www.today.ucla.edu/portalut/ 080220_wearable-
kidney.aspx). 
 
although except for the pulsing double 
blood/dialysate pump which increases efficiency 
and makes the device less prone to clotting it is a 
rather conventional arrangement (15). Ronco´s 
group in Vicenza builds their ViWAK (abbreviation 
of Vicenza WAK) on a PD principle (Fig. 6).  
 
Fig. 6: PD-based WAK of the Vicenza group 
(ViWAK): belt showerproof construction; daily 
treatment cycle: fill-in, 2 hours dwell time followed 
by 10 hours recirculation via double-lumen 
catheter and disposable sorbent cartridges, use of 
icodextrin over night to ensure sufficient fluid 
removal (http://content.karger.com/ProdukteDB/ 
produkte.asp?Aktion=ShowPDF&ArtikelNr=10777
5&Ausgabe=233672&ProduktNr=223997&filenam
e=107775.pdf). 
 
Peritoneal dialysis solution circulates via a double 
lumen PD catheter through a battery of sorbent 
cartridges and daily clearance of urea is assumed to 
reach about 11 litres (16). Concurrently, they work 
on a continuous wearable purely ultrafiltration 
device (WUF) intended for cardiac patients with 
fluid overload resistant to diuretics (17). Its first 
“belt” version clearly bespeaks co-operation with 
Victor Gura but the projected “vest-like” innovation 
already shows elegance of the “Ital-design” - Fig. 7.   
 
Fig. 7: The continuous ultrafiltration device from 
the Vicenza group of C. Ronco (left picture - the 
first version of the device, right picture – vest-
contained WUF intended primarily for cardiac 
patients), (Ronco C et al: Nefrologia, 2011, 
31(1):9-16; http://www.revistanefrologia.com)  
 
Considered is also use of this device in HD 
patients during the interdialytic period - it could 
eliminate the need for high ultrafiltration rates 
during HD, responsible for most episodes of 
intradialytic hypotensions. However, this idea is by 
no means new, it has been suggested by Shaldon 
already at the beginning of the eighties (18) but 
developmental priorities in dialysis field at that 
time were different. How interesting the concept is 
becomes obvious from recent findings of Bleyer 
(19) on significantly higher mortality from 
cardiovascular reasons on the last day of the longest 
interdialytic interval (usually three days on thrice 
weekly HD schedule Monday-Wednesday-Friday) 
when patient´s overhydration reaches its maximum. 
Growing interest in WAK is documented also by 
the first “World conference on portable-wearable 
systems for dialysis and ultrafiltration” held in 
Vicenza in 2010. Although it did not bring any 
break-through concepts, it provided very good 
overview of current state of the art in the WAK 
field. Noteworthy was the presentation of 
Harashima (20) who presented a system mimicking 
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tubular concentrating function by combination of 
electrodialysis, dialysis and filtration. The device 
was able to increase urea concentration in the test 
solution 2 to 3 times. Information was also 
provided on the European project “Nephron Plus” 
(21). This joint project of ten subjects (industry, 
universities, renal foundations) from six different 
European countries with total budget of about 6 
mil. Euro, of which over 4 mil. are to be provided 
by EU within the FP7, should result in an European 
WAK by 2014. 
In 2011, the first WAK to be commercially 
available was introduced by a Singapore company 
AWAK Technologies at the ERA/EDTA Congress 
in Prague - Fig. 8. It is a PD-based device similar to  
 
Fig. 8: PD-based WAK of AWAK Technologies, 
Singapore – the first WAK to be commercialized 
(Europe - CE mark still needed, US – FD clearance 
needed), (www.awak.com/wearable_dialysis ). 
 
the Vicenza ViWAK construction. With daily 
running time of 19-21 hours, 2 to 3 exchanges of 
the sorbent cartridge are needed (22). Interesting is 
the fact that AWAK Technologies has utilised a 
rather old patent of Roberts and Lee from 1993(!) 
Recently, some new technologies potentially 
applicable in WAK have been developed. 
Magnetically assisted dialysis uses ferromagnetic 
nanoparticles covered with a sorbent (23). They are 
infused in the extracorporeal circuit, where the 
sorbent binds waste metabolites, and are again 
removed in a magnetic separator before returning 
the blood in vascular system. 
Because the particles diameter is only 30 nm, i.e. 
200 times smaller than erythrocyte, their infusion 
directly in vascular system with an implanted 
magnetic separator, i.e. without the need to create 
an extracorporeal circuit, may prove feasible in 
future. 
Another promising direction is application of 
nanotechnological processes in membrane 
manufacture. It should enable to create membranes 
with solute-specific pores which would allow 
passage of only selected waste metabolites or only 
solutes to be resorbed from primary filtrate. The 
latter variant is used in Nissenson project of WAK 
(24) – Fig. 9. It combines solute unspecific 
filtration via a conventional high-flux membrane 
and subsequent filtration of the filtrate across a 
nanotechnologically manufactured membrane 
permeable only for solutes to be retained in the 
body. The secondary filtrate with those substances 
would then be returned to blood (mimicking tubular 
resorption) while the remaining waste solutes not 
able to pass through the membrane would be 
discarded (mimicking final urine in biological 
kidney). 
 
Fig. 9: Sorbent-free WAK (Artificial nephron) of 
Nissenson and co-workers: “Glomerular” stage 
realized by a conventional solute-unspecific HF 
membrane, created filtrate further processed in 
“tubular” section with nanotechnologically 
manufactured T-membrane allowing passage of 
solutes to be resorbed (http://content.karger.com/ 
ProdukteDB/produkte.asp?Aktion=ShowAbstract&
ProduktNr=223997&ArtikelNr=85882). 
  
No sorbents are needed also in bio-artificial 
kidney of David Humes (25). Principle of his 
device is depicted in Fig. 10: Blood of the patient to 
be treated enters first a conventional haemofilter.  
Fig. 10: WAK construction with bioartificial 
tubulus (D. Humes, 2007): Conventional 
haemofilter is used in the first (glomerular) stage, 
generated filtrate further processed in a special 
dialyzer with inner surface of the fibres coated with 
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monolayer of living epithelial tubular cells to do the 
same resorption as in tubules of biological kidney. 
Membrane in the bio-artificial tubulus protects 
cells of a donor from direct contact with blood of 
the patient treated with the device. 
 
Filtrate from the first filter proceeds to the second 
capillary membrane device. Inner surface of its 
fibres are covered by a monolayer of living human 
tubular epithelial cells. Those cells do precisely the 
same what they normally do in tubules of a 
biological kidney – they resorb all for the body 
valuable substances from the primary filtrate to the 
blood which brought from the first filter to the 
outside fibres compartment of the second one. The 
device worked very well in the first clinical trials.  
 
Fig. 10: WAK construction with bioartificial 
tubulus (D. Humes, 2007): Conventional 
haemofilter is used in the first (glomerular) stage, 
generated filtrate further processed in a special 
dialyzer with inner surface of the fibres coated with 
monolayer of living epithelial tubular cells to do the 
same resorption as in tubules of biological kidney. 
Membrane in the bio-artificial tubulus protects 
cells of a donor from direct contact with blood of 
the patient treated with the device. 
 
Problems appeared when the cells started to grow 
and form thicker layer. However, Saito in Japan 
seems to have found a remedy recently – he started 
adding growth inhibition factor to the monolayer 
substrate (26) and the monolayer character of the 
cellular coating remained preserved. This success 
made him to consider construction of also the 
“glomerular” part of the device in a similar 
“bioartificial” way. To make the list of 
“bioartificial” construction complete, the device 
developed by Fissel and Roy must be mentioned 
(27). In principle, it is similar to Humes´s 
arrangement but from the very beginning it is being 
developed as an implantable device. Fig. 11 shows 
a picture of their device recently released on the 
Internet. 
WAK pitfalls and realistic expectations 
 
Reasons for the development of WAK do appear 
clear and reasonable: attenuation or complete 
removal of unphysiological variation in body 
chemistry seen in intermittent therapy (WAK has 
always been perceived as a synonymum to 
continuously running device), augmented in the last 
decade by an economic factor – expectations of 
lower treatment costs of RRT in chronic renal 
failure patients. Utilisation of convective principle 
(haemofiltration) is certainly better than diffusion-
based process (haemodialysis) as the spectrum of 
solutes transported convectively across an artificial 
membrane is much closer to sieving spectrum of 
glomerular membrane and does not depend on 
molecular weight as is the case with diffusion. To 
mimic the second stage of nephron function – 
tubular resorption, most current WAK constructions 
rely on sorbents. Indeed, they can effectively 
eliminate huge amount of dialysis or substitution 
fluid needed in conventional therapies. However, an 
ideal sorbent which would have a mirror-like 
sorption spectrum compared to tubular function 
(what is not resorbed in tubules goes to “drain” as 
the final urine while what is not adsorbed on a 
sorbent remains in the body) has yet to be 
developed. Because of saturation with adsorbed 
waste metabolites, sorbent cartridges also need 
rather frequent exchanges. There are theoretically 
two technical alternatives to sorbent use – 
combination of electrodialysis, filtration and 
osmosis or membranes with selective permeability 
to waste metabolites only (to be manufactured by a 
nanotechnological process). Unfortunately, 
development of neither of those two possibilities is 
advanced enough to allow us to think about routine 
application in a near future. 
To compare prospects and expectations of PD- 
and HD(HF)-based WAK constructions, there are 
three factors to consider. Easy control of fluid 
removal to continuously control patient hydration 
presents no problem in HD(HF)-based devices with 
direct access to blood, while it is much more 
difficult in PD-based devices. Precisely the 
opposite is safety of the access. Access to vascular 
system needed for an externally worn WAK is the 
major risk factor of those constructions. In fact, 
subjective fears of undetected disconnection of the 
extracorporeal circuit on the side of both physicians 
and patients themselves may entirely hamper 
introduction of an even perfect device into clinical 
use. Much better in this respect would be an 
implantable WAK permanently incorporated in 
patient´s vascular system once the issue of sorbent 
cartridge exchange is solved (e.g. by magnetically 
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assisted HD). The last issue to consider is degree of 
improvement in treatment physiology offered by a 
particular WAK construction. In this expectation, 
both systems are about equal. Continuous 
extracorporeal blood cleansing has been a standard 
treatment modality in acute renal failure for the last 
25 to 30 years. Benefits of a truly continuously run 
PD-based device may be less apparent. But it is not 
just replacement of 10 to 12 litres of solution per 
day, as used in currently the most wide-spread PD 
modality – the CAPD (continuous ambulatory 
peritoneal dialysis) by only 2 litres and 2 to 3 
sorbent cartridges. Circulation of the peritoneal 
solution via the cartridge keeps concentration of all 
catabolites in it permanently low which in turn 
keeps the difussional transport across the peritoneal 
membrane high all the time, not just at the 
beginning of each exchange as in conventional 
CAPD. It is very well seen on measurement of total 
excreted amount of urea on a physical model of PD 
shown in Fig. 12.  
 
 
 
Fig. 12: Comparison of the total removed amount 
of urea during a simulated 3-hour PD: bottom 
curve – conventional PD exchange (rapid decrease 
in waste metabolites transport due to increasing 
concentration in dialysate during the exchange); 
upper curve – PD with the same amount of 
dialysate cleaned on-line by circulation through an 
external dialyzer keeping the transport high all the 
time (adapted from Ettler L: Physical model of 
peritoneal dialysis, MSc Thesis, Charles University 
Medical School, Prague, 2000). 
 
In the TAC/TAD plot (Fig. 1), excretion of this 
magnitude would add to already low TAD value 
(achieved by conventional CAPD) also TAC values 
quite close to the “healthy region”. 
Those few bio-artificial or hybrid constructions 
developed so far have been surprisingly successful 
in in vivo trials unparalleled in purely technical 
WAK devices. Large scale application of those 
devices would however need to build up an entirely 
new infrastructure considering their rather short 
storage time and possible need of nutrient delivery 
during the idle storage time to keep the cell cultures 
alive.  
Last but not least factor to consider in estimation 
of future needs and development directions of renal 
replacement therapy is development in the field of 
regenerative medicine, which, however, is well 
beyond the scope of this article. 
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